Avapritinib. PDGFR-alpha and KIT mutant inhibitor, Treatment of gastrointestinal stromal tumor, Treatment of systemic mastocytosis

2019 ◽  
Vol 44 (3) ◽  
pp. 187
Author(s):  
J. Gras
2013 ◽  
Vol 14 (8) ◽  
pp. 941-956 ◽  
Author(s):  
Sabrina Angelini ◽  
Gloria Ravegnini ◽  
Jonathan A Fletcher ◽  
Francesca Maffei ◽  
Patrizia Hrelia

Author(s):  
Rajashekar T. S. ◽  
Shruthi Madhavi G. ◽  
Suresh Kumar Kuppuswamy

<p class="abstract">Imatinib mesylate (IM) is a tyrosine kinase inhibitor approved for chronic myeloid leukemia, gastrointestinal stromal tumor and few dermatological conditions such as dermatofibrosarcoma protruberans, systemic sclerosis and systemic mastocytosis among other conditions. It is known to cause non lichenoid eruptions commonly and rarely it can cause lichenoid drug eruption. Small plaque parapsoriasis is a monoclonal T cell disorder with clinical similarity to psoriasis characterised by small sized plaques with digitate appearance.We report a case of 75 year old male on IM for gastrointestinal stromal tumor who presented with clinical features suggestive of small plaque parapsoriasis which was eventually proved as lichenoid drug eruption secondary to IM on biopsy. IM was identified as the offending drug and the eruptions subsided one month after discontinuation of the drug.</p>


JCI Insight ◽  
2020 ◽  
Author(s):  
Shuai Ye ◽  
Dinara Sharipova ◽  
Marya Kozinova ◽  
Lillian R. Klug ◽  
Jimson W. D'Souza ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document